Aberdeen Asset Management PLC UK grew its position in Henry Schein, Inc. (NASDAQ:HSIC) by 23.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,345 shares of the company’s stock after buying an additional 4,669 shares during the period. Aberdeen Asset Management PLC UK’s holdings in Henry Schein were worth $4,456,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Lee Financial Co purchased a new stake in shares of Henry Schein in the 2nd quarter valued at approximately $161,000. Westside Investment Management Inc. purchased a new stake in shares of Henry Schein in the 1st quarter valued at approximately $168,000. JNBA Financial Advisors purchased a new stake in shares of Henry Schein in the 1st quarter valued at approximately $170,000. Peddock Capital Advisors LLC grew its stake in shares of Henry Schein by 29.1% in the 1st quarter. Peddock Capital Advisors LLC now owns 1,097 shares of the company’s stock valued at $186,000 after buying an additional 247 shares during the period. Finally, Van ECK Associates Corp grew its stake in shares of Henry Schein by 5.7% in the 1st quarter. Van ECK Associates Corp now owns 1,138 shares of the company’s stock valued at $193,000 after buying an additional 61 shares during the period. 89.11% of the stock is owned by institutional investors and hedge funds.

In other Henry Schein news, SVP Paul Rose sold 2,126 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $172.51, for a total transaction of $366,756.26. Following the completion of the sale, the senior vice president now directly owns 17,841 shares in the company, valued at $3,077,750.91. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.27% of the stock is currently owned by insiders.

Several analysts have recently weighed in on HSIC shares. Northcoast Research raised shares of Henry Schein from a “neutral” rating to a “buy” rating and set a $109.00 price target for the company in a research note on Monday, August 7th. Zacks Investment Research raised shares of Henry Schein from a “hold” rating to a “buy” rating and set a $103.00 price target for the company in a research note on Friday, June 16th. UBS AG reissued a “buy” rating on shares of Henry Schein in a research note on Friday. Jefferies Group LLC reissued a “hold” rating and issued a $88.50 price target on shares of Henry Schein in a research note on Friday, July 21st. Finally, Credit Suisse Group reissued a “hold” rating and issued a $80.00 price target on shares of Henry Schein in a research note on Thursday, July 13th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $93.30.

Shares of Henry Schein, Inc. (NASDAQ:HSIC) opened at 82.88 on Friday. The firm has a market capitalization of $6.55 billion, a price-to-earnings ratio of 12.11 and a beta of 1.10. Henry Schein, Inc. has a 12-month low of $82.16 and a 12-month high of $186.99. The firm’s 50-day moving average is $170.49 and its 200-day moving average is $175.55.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, August 8th. The company reported $0.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.86 by $0.02. Henry Schein had a net margin of 4.59% and a return on equity of 19.91%. The firm had revenue of $3.06 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same period in the previous year, the firm earned $0.82 earnings per share. Henry Schein’s revenue was up 6.4% compared to the same quarter last year. Equities research analysts forecast that Henry Schein, Inc. will post $7.27 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/16/aberdeen-asset-management-plc-uk-has-4-46-million-stake-in-henry-schein-inc-hsic.html.

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Stock Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related stocks with our FREE daily email newsletter.